Umeclidinium bromide/vilanterol

< Umeclidinium bromide

Umeclidinium bromide/vilanterol
Umeclidinium bromide (TOP), vilanterol (BOTTOM)
Combination of
Umeclidinium bromideMuscarinic antagonist
VilanterolUltra-long-acting β2 agonist
Clinical data
Trade namesAnoro Ellipta, others
AHFS/Drugs.comProfessional Drug Facts
License data
Pregnancy
category
  • AU: B3
Routes of
administration
Inhalation
ATC code
Legal status
Legal status
  • AU: S4 (Prescription only)
  • UK: POM (Prescription only)
  • US: ℞-only
  • EU: Rx-only
Identifiers
CAS Number
KEGG

Umeclidinium bromide/vilanterol, sold under the brand name Anoro Ellipta, among others, is a fixed-dose combination medication for the treatment of chronic obstructive pulmonary disease (COPD). It is administered by inhalation.

The most common side effects include upper respiratory tract infections, urinary tract infections, pharyngitis, sinusitis, nasopharyngitis, headache, cough, oropharyngeal pain, constipation and dry mouth.

In 2022, it was the 211th most commonly prescribed medication in the United States, with more than 1 million prescriptions.